# Use of genetically encoded, light-gated ion translocators to control tumorigenesis

Source: https://onco.cc/key-papers/paper-chernet-oncotarget/  
OnCo record `paper-chernet-oncotarget` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Paper cited by one term page, indexed on Europe PMC as PubMed record 26988909 and published in Oncotarget; the citing page links this DOI, which is how the record was matched.

## Summary

It has long been known that the resting potential of tumor cells is depolarized relative to their normal counterparts. More recent work has provided evidence that resting potential is not just a readout of cell state: it regulates cell behavior as well. Thus, the ability to control resting potential in vivo would provide a powerful new tool for the study and treatment of tumors, a tool capable of revealing living-state physiological information impossible to obtain using molecular tools applied to isolated cell components. Here we describe the first use of optogenetics to manipulate ion-flux mediated regulation of membrane potential specifically to prevent and cause regression of oncogene-induced tumors. Injection of mutant-KRAS mRNA induces tumor-like structures with many documented similarities to tumors, in Xenopus tadpoles. We show that expression and activation of either ChR2D156A, a blue-light activated cation channel, or Arch, a green-light activated proton pump, both of which hyperpolarize cells, significantly lowers the incidence of KRAS tumor formation. Excitingly, we also demonstrate that activation of co-expressed light-activated ion translocators after tumor formation significantly increases the frequency with which the tumors regress in a process called normalization. These data demonstrate an optogenetic approach to dissect the biophysics of cancer. Moreover, they provide proof-of-principle for a novel class of interventions, directed at regulating cell state by targeting physiological regulators that can over-ride the presence of mutations.

Indexed on Europe PMC as PubMed record 26988909 (DOI 10.18632/oncotarget.8036). Matched by DOI alone: one term page cites this DOI among its external links (the pages are listed under Related), and this page was written so that the citation resolves inside OnCo. No figure has been checked by an editor.

## Fields

- Kind: Key paper
- Last checked: 2026-09-22
- Tags: europepmc-ingest
- Journal: Oncotarget
- Year: 2016
- DOI: 10.18632/oncotarget.8036
- Authors: Chernet BT, Adams DS, Lobikin M, et al.
- What it means: One term page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
- Caveats: Matched to the citing OnCo records by DOI alone; the summary reproduces the Europe PMC abstract and no figure has been verified against the full paper.

## Sources

- Oncotarget 2016: https://doi.org/10.18632/oncotarget.8036
- PubMed: https://pubmed.ncbi.nlm.nih.gov/26988909/
- Europe PMC: https://europepmc.org/article/MED/26988909

## Connected records

- terms: [Bioelectric theory of cancer (Levin)](https://onco.cc/terms/bioelectric-theory-of-cancer/)
- journals: [Oncotarget](https://onco.cc/journals/oncotarget/)

---
JSON: https://onco.cc/api/v1/entities/paper-chernet-oncotarget.json